A behavioral study of the changes in the CNS of mice after subchronic treatment with the dopamine autoreceptor agonist 3-PPP
Hjorth, S.; Jackson, D.; Carlsson, A.; Lindberg, P.
Psychopharmacology Bulletin 18(4): 149-152
1982
ISSN/ISBN: 0048-5764 PMID: 7156279 Document Number: 189360
Document emailed within 1 workday
Related Documents
Okuyama, S.; Shimamura, H.; Hashimoto, S.; Aihara, H. 1986: Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats Archives Internationales de Pharmacodynamie et de Therapie 284(2): 246-254Antelman, S.M.; Chiodo, L.A. 1981: Dopamine autoreceptor subsensitivity: a mechanism common to the treatment of depression and the induction of amphetamine psychosis Biological Psychiatry 16(8): 717-727
Antelman, S.M.; Chiodo, L.A. 1981: Repeated antidepressant treatments induce a long-lasting dopamine autoreceptor subsensitivity: is daily treatment necessary for clinical efficacy? Psychopharmacology Bulletin 17(1): 92-94
Skuza, G.; Kolasiewicz, W. 2001: Repeated treatment with SA4503, a selective sigma1 receptor agonist, up-regulates alpha-adrenergic system. a behavioral study Polish Journal of Pharmacology 53(5): 547-550
Gangadhar, B.N.; Pradhan, N.; Mayanil, C.S. 1987: Dopamine autoreceptor down-regulation following repeated electroconvulsive shock Indian Journal of Medical Research 86: 787-791
Malmberg; Mikaels; Mohell, N. 1998: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding Journal of Pharmacology and Experimental Therapeutics 285(1): 119-126
Ceccherini-Nelli, A.; Guazzelli, M. 1994: Treatment of refractory OCD with the dopamine agonist bromocriptine Journal of Clinical Psychiatry 55(9): 415-416
Eijsbouts, A.; van den Hoogen, F.; Laan, R.F.; Hermus, R.M.; Sweep, F.C.; van de Putte, L. 1999: Treatment of rheumatoid arthritis with the dopamine agonist quinagolide Journal of Rheumatology 26(10): 2284-2285
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Kohli, J.D.; Goldberg, L.I.; Volkman, P.H.; Cannon, J.G. 1978: N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist Journal of Pharmacology and Experimental Therapeutics 207(1): 16-22
Priestly, B.G.; Plaa, G.L. 1976: Hepatic function after acute of subchronic nicotine administration in untreated mice and mice treated with hepatotoxic chemicals Archives Internationales de Pharmacodynamie et de Therapie 223(1): 132-141
Fuller, R.W.; Clemens, J.A.; Hynes, M.D. 1982: Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia Journal of Clinical Psychopharmacology 2(6): 371-375
Kozlovskiĭ, V.L. 2012: Effect of haloperidol on changes in development of spontaneous catalepsy during subchronic injections of dopamine agonists and antagonists Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 3: 75-80
Breese, G.R.; Baumeister, A.A.; McCown, T.J.; Emerick, S.G.; Frye, G.D.; Crotty, K.; Mueller, R.A. 1984: Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine Journal of Pharmacology and Experimental Therapeutics 231(2): 343-354
Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. 1995: 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity Journal of Pharmacology and Experimental Therapeutics 274(1): 329-336
Batool, F.; Haleem, D.J. 2008: Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats Pakistan Journal of Pharmaceutical Sciences 21(4): 411-420
Van den Berg, K.J.; Lammers, J.H.; Hoogendijk, E.M.; Kulig, B.M. 1996: Changes in regional brain GFAP levels and behavioral functioning following subchronic lead acetate exposure in adult rats Neurotoxicology 17(3-4): 725-734
Muraki, I. 2001: Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate Hokkaido Journal of Medical Science 76(2): 57-70
Kropp, P.; Gerber, W.D.; Keinath-Specht, A.; Kopal, T.; Niederberger, U. 1997: Behavioral treatment in migraine. Cognitive-behavioral therapy and blood-volume-pulse biofeedback: a cross-over study with a two-year follow-up Functional Neurology 12(1): 17-24